{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Keratoconjunctivitis&page=2",
    "query": {
      "condition": "Keratoconjunctivitis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Keratoconjunctivitis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:57:14.772Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01817582",
      "title": "Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Lotemax",
          "type": "DRUG"
        },
        {
          "name": "Restasis",
          "type": "DRUG"
        },
        {
          "name": "Soothe® Lubricant Eye Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2013-05-17",
      "completion_date": "2014-01-10",
      "has_results": true,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817582"
    },
    {
      "nct_id": "NCT07519902",
      "title": "An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Persistent Corneal Epithelial Defect"
      ],
      "interventions": [
        {
          "name": "Cenegermin",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-04-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Chesterfield, Missouri • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chesterfield",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07519902"
    },
    {
      "nct_id": "NCT03925727",
      "title": "Tavilermide Ophthalmic Solution for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca",
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Tavilermide ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mimetogen Pharmaceuticals USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 623,
      "start_date": "2019-03-28",
      "completion_date": "2020-06-11",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03925727"
    },
    {
      "nct_id": "NCT01027013",
      "title": "Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes",
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "rebamipide 2% ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "placebo eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kubota Vision Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2009-12",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2012-01-11",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 5,
      "location_summary": "Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027013"
    },
    {
      "nct_id": "NCT01900249",
      "title": "To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "R348 Ophthalmic Solution, 0.2%",
          "type": "DRUG"
        },
        {
          "name": "R348 Ophthalmic Solution, 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 204,
      "start_date": "2013-07",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-03",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 20,
      "location_summary": "Artesia, California • Petaluma, California • Rancho Cardova, California + 16 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Rancho Cardova",
          "state": "California"
        },
        {
          "city": "Parker",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900249"
    },
    {
      "nct_id": "NCT00411827",
      "title": "Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "PRK with conjunctival impression cytology before and after surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "LASIK with conjunctival impression cytology before and after surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Walter Reed National Military Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "21 Years to 40 Years"
      },
      "enrollment_count": 146,
      "start_date": "2008-01",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2024-09-20",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00411827"
    },
    {
      "nct_id": "NCT00201955",
      "title": "Study of Rebamipide Eye Drops to Treat Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "Rebamipide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 740,
      "start_date": "2004-05",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2006-11-02",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Little Rock, Arkansas + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Inglewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201955"
    },
    {
      "nct_id": "NCT02665234",
      "title": "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "1% Tavilermide Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mimetogen Pharmaceuticals USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2016-01",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02665234"
    },
    {
      "nct_id": "NCT02592330",
      "title": "Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Limbal Stem Cell Deficiency"
      ],
      "interventions": [
        {
          "name": "Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft",
          "type": "PROCEDURE"
        },
        {
          "name": "Cultivation of Limbal epithelial cells into a graft",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CALEC Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 23,
      "start_date": "2016-08-01",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02592330"
    },
    {
      "nct_id": "NCT05310422",
      "title": "Safety Study of Tivanisiran to Treat Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Tivanisiran sodium ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sylentis, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 301,
      "start_date": "2022-03-24",
      "completion_date": "2023-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-05-22T06:57:14.772Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Glendale, California + 21 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05310422"
    }
  ]
}